Mereo BioPharma Group plc (MREO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Mereo BioPharma reported revenue of $500,000. Net income was -$41.9M (a -8375.6% net margin), or -$0.05 per diluted share. Operating margin was -8021.4%. Operating activities generated -$31.0M of cash, leaving -$31.0M of free cash flow. At fiscal year end, Mereo BioPharma held $45.9M in total assets against $5.0M in total liabilities, including $41.0M of cash and equivalents.
Open the full interactive Mereo BioPharma financials → Quarterly statements, key ratios, valuation history and price charts.
Mereo BioPharma Key Stats
| Share Price | $0.32 |
|---|---|
| Market Cap | $51.4M |
| 52-Week Range | $0.24 – $2.31 |
| Shares Outstanding | 803.6 million (basic, 2026 Q2) |
Mereo BioPharma Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $10.0M | $0 | $500,000 |
| Operating Income | -$28.4M | -$47.4M | -$40.1M |
| Pre-Tax Income | -$30.0M | -$43.3M | -$41.9M |
| Income Tax | -$532,000 | $0 | $0 |
| Net Income | -$29.5M | -$43.3M | -$41.9M |
| Diluted EPS | -$0.04 | -$0.06 | -$0.05 |
Mereo BioPharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.0M | -$7.4M | -$6.7M | -$7.0M |
| Diluted EPS | -$0.01 | -$0.01 | -$0.01 | -$0.01 |
Mereo BioPharma Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $57.4M | $69.8M | $41.0M |
| Current Assets | $63.8M | $74.8M | $45.0M |
| Total Assets | $66.5M | $76.4M | $45.9M |
| Current Liabilities | $9.5M | $13.8M | $4.3M |
| Total Long-Term Debt | $4.4M | — | — |
| Total Liabilities | $16.0M | $15.4M | $5.0M |
| Shareholders' Equity | $50.5M | $61.0M | $40.9M |
Mereo BioPharma Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$21.1M | -$32.8M | -$31.0M |
| Cash From Investing | -$419,000 | -$699,000 | -$20,000 |
| Cash From Financing | $8.0M | $46.1M | $327,000 |
| Free Cash Flow | -$21.1M | — | -$31.0M |
Figures from Mereo BioPharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Mereo BioPharma financials page for every line item.
Mereo BioPharma Company Profile
| Ticker | MREO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | London |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001719714 |
Frequently Asked Questions
What was Mereo BioPharma's revenue in fiscal 2025?
Mereo BioPharma (MREO) reported revenue of $500,000 for fiscal 2025.
What is Mereo BioPharma's annual revenue history?
Mereo BioPharma's annual revenue by fiscal year: 2023: $10.0M; 2024: $0; 2025: $500,000.
What was Mereo BioPharma's net income in fiscal 2025?
Mereo BioPharma reported net income of -$41.9M for fiscal 2025.
What was Mereo BioPharma's earnings per share (EPS) in fiscal 2025?
Mereo BioPharma's diluted EPS was -$0.05 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Mereo BioPharma generate in fiscal 2025?
Mereo BioPharma generated -$31.0M of free cash flow in fiscal 2025.
What was Mereo BioPharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Mereo BioPharma reported revenue of $0.
How many shares of Mereo BioPharma are outstanding?
Mereo BioPharma reported a weighted average of 803.6 million basic shares outstanding in 2026 Q2.
What is Mereo BioPharma's market cap?
Based on its latest closing price, Mereo BioPharma (MREO) has a market capitalization of about $51.4M.
When does Mereo BioPharma's fiscal year end?
Mereo BioPharma's fiscal year end, as registered with the SEC, is December 31.
Where is Mereo BioPharma headquartered?
Mereo BioPharma lists its business address in London in its SEC filings.